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The introduction of new technology into the clinical
arena mandates a careful balance between the need for
prompt, universal access to promising interventions and the
recognition that further refinements could still be necessary
because the assessment of clinical performance may be
incomplete even after initial experimental trials have been
concluded. This is the case for devices that have received a
seal of approval from the Food and Drug Administration
(FDA) or, for that matter, for new procedures that have
gained a sufficient degree of legitimacy in the academic
literature to drive their adoption by the medical community
at large. It has been a little more than 2 years since the first
two systems for the endovascular repair of abdominal aortic
aneurysms were approved for commercial use by the FDA
on the basis of 1-year follow-up data. During the interven-
ing 2 years, more than 20,000 of these devices have been
implanted in the United States, despite the fact that implant
data exceeding 3 years of follow-up are available for only a
few hundred of each of the two proprietary systems. Late
complications are now being recognized with increasing
frequency, but the extent of these problems and their
relationship to device malfunction and deployment, patient
selection, or inadequate postoperative surveillance have yet
to be fully defined.
In this issue of the Journal of Vascular Surgery, Bern-
hard et al1 provide a detailed accounting of the reported
cases of aneurysm rupture after endovascular repair with
one of the two systems that have received FDA approval. In
a careful review of 686 patients treated with Guidant/EVT
endografts (Indianapolis, Ind) under FDA protocols, five
instances of aneurysm rupture were identified, all of which
were associated with first generation tube grafts. Two ad-
ditional cases of rupture have been documented among a
larger cohort of patients in whom Guidant/EVT en-
dografts were implanted after FDA market approval was
granted on September 28, 1999. In both cases, the aneu-
rysm was treated with a tube graft, albeit a second genera-
tion device in which hook fracture was not a contributing
factor. Notably, the authors’ analysis of the varying etiolo-
gies underlying the clinical failure of endovascular repair is
discussed in the context of 40 additional ruptures after
implantation of AneuRx, MinTec-Stentor, Talent, Van-
guard, or other off-label devices that have been reported in
the literature since 1995. As one might expect, most fail-
ures were caused by device failure, aneurysm remodeling,
and inappropriate patient selection or device deployment,
with an overall rupture-associated mortality rate of 50% in
the entire collected series. Although aneurysm rupture was
most often associated with a type I or type III endoleak, this
catastrophic event also occurred among patients who had
no discernable endoleak or aneurysm expansion. Thus, in
the context of the ongoing debate surrounding endograft
efficacy, it is certainly appropriate to question whether, in a
large population of treated patients, overall rupture risk can
ever be reduced to zero after endografting, even in the
framework of a close surveillance program. In certain pa-
tient subgroups, such as younger patients who are at low
risk for surgical intervention, the mere reduction of the risk
for aneurysm rupture in the absence of complete protection
may not sufficiently compensate for the acknowledged
limitations of open surgical repair.
The article by Bernhard and his colleagues clearly illus-
trates that the potential for a catastrophe exists after place-
ment of an endovascular graft. Of greater concern, how-
ever, is the absence of a true measure of the magnitude of
this problem within the larger clinical community. Strictly
speaking, it would be premature to conclude that clinical
failure of any commercial endograft device has been an
infrequent event after its market approval. To date, pub-
lished estimates of the incidence of aneurysm rupture and
open surgical conversion after endograft repair have been
largely confined to reports that have originated from FDA-
regulated clinical trials or, otherwise, from highly moti-
vated groups of dedicated investigators. In these series, the
treating endovascular surgeons have been uniformly well
trained and supervised in device deployment, patient selec-
tion, and postoperative surveillance. In many cases the
clinical sites were subjected to outside monitoring, the
collected data were carefully scrutinized, and the reporting
of adverse events was mandated. With these conditions, it
has been reassuring to note that the annual reported inci-
dence rate of aneurysm rupture generally has been less than
1%.2-4 Ultimately, however, the measured impact of device-
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related technology is determined by the ease with which it
can be safely adopted by a larger set of users in settings that
extend well beyond the initial group of clinical investiga-
tors.
Postmarket surveillance of adverse events after the
adoption of any new technology by the broader clinical
community is far less rigorous than in a clinical trial, and the
potential for underreporting device-related or procedure-
related complications remains a substantial problem. This
may be attributed to a number of reasons, such as concerns
over medical liability, personal embarrassment regarding an
adverse outcome, and perhaps in no small measure, the
burden of appropriately collecting and reporting the requi-
site data. Nonetheless, the recognition and timely determi-
nation of the prevalence of adverse events—whether aneu-
rysm rupture, elective conversion, or the necessity for a
secondary intervention—provide the primary mechanisms
for both the medical community and industry to rapidly
address correctable device-related and procedure-related
problems and, if necessary, to remove truly poor devices
from the marketplace.
Problems with coronary stents, heart valves, artificial
hips, and antiarrhythmia devices existed long before the
introduction of endovascular grafts, so the need to monitor
existing and newly released devices in the clinical commu-
nity has been recognized for some time. In the United
States, manufacturers and healthcare facilities are required
to report all known device-related complications to the
FDA; however, physicians are under no such obligation,
and all of their reporting is voluntary. In an attempt to
encourage the submission of relevant data, the FDA has
created a safety information and adverse event-reporting
program for drugs and devices known as MedWatch
(www.fda.gov/medwatch), which is available to capture
device-related or procedure-related problems. In this con-
text, recent efforts by the Lifeline Registry of Endovascular
Aneurysm Repair to initiate a pilot program for online
collecting of postmarket data should be applauded, and
efforts to expand and coordinate this program with the
FDA should be encouraged.5 There is an obvious need for
a universal registry to collect surveillance data to improve
patient management through rapid access to postmarketing
outcomes and to identify the inappropriate use of off-label
devices. Moreover, the development of this kind of clinical
registry potentially could shorten the review period of an
investigational device by providing additional information
concerning the community-based performance of similar
or previous versions of the device and by persuading the
FDA that there is a mechanism for vigilance once such a
product enters the marketplace.6 In the absence of a system
to ensure accurate and complete reporting that extends
beyond a few academic medical centers, the potential exists
that clinical recommendations will be based, at least in part,
on the principles of “hear no evil, see no evil, and speak no
evil.” As vascular surgeons, we must ensure that all blinders
are removed as we continue to drive along the endovascular
highway, for by having the clearest view of the road ahead
will we provide the greatest service to our patients.
REFERENCES
1. Bernhard VM, Mitchell RS, Matsumura JS, Brewster DC, Decker M,
Lamparello P, et al. Ruptured abdominal aortic aneurysm following
endovascular repair. J Vasc Surg. In press 2002.
2. Harris PL, Vallabhaneni SR, Desgranges P, Becquemin JP, van Mar-
rewijk C, Laheij RJ. Incidence and risk factors of late rupture, conver-
sion, and death after endovascular repair of infrarenal aortic aneurysms:
the EUROSTAR experience. J Vasc Surg 2000;32:739-49.
3. Becker GJ, Kovacs M, Mathison MN, Katzen BT, Benenati JF, Zemel
G, et al. Risk stratification and outcomes of transluminal endografting
for abdominal aortic aneurysm: 7-year experience and long-term follow-
up. J Vasc Intervent Radiol 2001;12:1033-46.
4. Zarins CK, White RA, Moll FL, Crabtree T, Bloch DA, Hodgson KJ, et
al. The AneuRx stent graft: four-year results and worldwide experience
2000. J Vasc Surg 2001;33(Suppl 2):S135-45.
5. Lifeline Registry of Endovascular Repair Steering Committee. Lifeline
Registry: collaborative evaluation of endovascular aneurysm repair. J
Vasc Surg 2001;34:1139-46.
6. The role of clinical data in postmarket surveillance of cardiovascular
devices. FDA workshop summary [internet]. Available at: www.fda.
gov/cdrh/postsurv/postscvwork.html.
Submitted Feb 7, 2002; accepted Feb 7, 2002.
Please see the related article by Dr Victor M. Bernhard
et al on pages 1155-62.
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